Pharsight

Restasis patents expiration

RESTASIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474979 ABBVIE Nonirritating emulsions for sensitive tissue
May, 2014

(10 years ago)

US8633162 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

US8648048 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

US8685930 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

US9248191 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

US8642556 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

US8629111 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(2 months from now)

Restasis is owned by Abbvie.

Restasis contains Cyclosporine.

Restasis has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Restasis are:

  • US5474979

Restasis was authorised for market use on 23 December, 2002.

Restasis is available in emulsion;ophthalmic dosage forms.

Restasis can be used as increase tear production in patients with keratoconjunctivitis sicca (dry eye)., increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)..

The generics of Restasis are possible to be released after 27 August, 2024.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's drug patent expiration?
More Information on Dosage

RESTASIS family patents

Family Patents